A lthough the traditional resection of esophageal adenocarcinoma (EAC) has been with esophagectomy, treatment for localized disease is moving increasingly from a surgical to endoscopic approach. 1, 2 National guidelines for treatment of EAC confined to the mucosa, ie, T1aN0M0 cancer, prefer endoscopic therapy (ET) over esophagectomy because of comparable survival and decreased morbidity. [3] [4] [5] [6] In contrast, esophagectomy continues to be recommended for EAC invading into the submucosa, ie, T1b cancers, because of the 15%-30% prevalence of lymph node involvement. [1] [2] [3] 7 However, investigations into ET for T1b are being performed. Pre-surgical staging with endoscopic ultrasound has reduced the risk of occult lymph node involvement, although its accuracy in early stage EAC varies from 65% to 93%. 2, [8] [9] [10] [11] [12] Of more use may be endoscopic mucosal resection, which allows for pre-surgical pathologic staging and identification of higher risk features, such as tumor diameter more than 3 cm, depth of invasion more than one-third into the submucosa, higher grade, and lymphovascular invasion. 13, 14 Despite these advances, national data suggest that to date, T1b EAC treated with ET has worse outcomes compared with esophagectomy. 1, 15, 16 Even so, rates of ET for T1b cancers in the United States are rising; in 2010, 20.9%
were treated with ET compared with 6.6% in 2004, mainly in patients aged 75 or older. 1 This may be due to poor surgical candidacy in these older patients. [17] [18] [19] [20] In addition, the risk of dying from competing comorbidities should be weighed against the risk of dying of cancer.
14 Finally, esophagectomy is a morbid procedure with persistently decreased quality of life. [21] [22] [23] For patients with already reduced life expectancy from comorbidities, it is unclear whether the relative gain in cancer-related survival with esophagectomy is worth the cost in quality of life.
The aim of our study was to develop and analyze a decision-analytic model investigating the effectiveness of esophagectomy versus ET for T1a and T1b EAC with respect to unadjusted life years, quality-adjusted life years (QALYs), and cost-effectiveness, varying combinations of age and comorbidity burden to explore whether these factors would change the optimal therapy.
Materials and Methods

Model Design
Decision-analytic Markov-state transition models were constructed in TreeAge Pro (TreeAge, Williamstown, MA) for T1aN0M0 and T1bN0M0 EAC (Figure 1 ). Health states included post-esophagectomy, post-ET, and dead. Possible causes of death included age-and comorbidity-related mortality, procedural mortality, and cancer-specific mortality. The Markov cycle length was 1 month. The simulation in the base case analysis began with a hypothetical cohort of 75-year-old men with T1a or T1bN0M0 EAC, not previously treated with radiation or chemotherapy, who were followed until death. In the ET arm, the simulated patient would undergo ET for the first 3 cycles. 13, 14 In both treatment arms, the patient could die of procedural mortality, stay in the same state, die of age-and comorbidity-related mortality, or die of cancer.
We estimated the comorbidity burden and associated mortality of our patients by using the Charlson comorbidity index. 24 In calculating our patients' comorbidity index, we excluded esophageal cancer and included only 3 scores: 0, 1, and 2þ. This is common practice in the surgical literature, because patients with comorbidity indices greater than 2 are usually excluded as surgical candidates. 25 We did not include age in our Charlson comorbidity index in order to account for risks related to age separately.
Parameter Estimates
Model parameters were estimated from the literature. Base case values and ranges used in sensitivity analyses are summarized in Table 1 .
Model Transition Probabilities and Calibration
Cancer-specific survival for T1b EAC treated with ET has only been reported in small studies with a wide range of estimates. Therefore, we calculated our own estimates of cancer-specific death for esophagectomy and ET on the basis of data from the Surveillance, Epidemiology, and End Results (SEER) database (Supplementary Methods). Because of small numbers of T1b tumors in the database, tumors categorized as "T1NOS" were combined into the T1b group (Supplementary Figure 1) . Kaplan-Meier curves were generated to compare overall survival between treatment groups ( Figure 2 ). Hazard rates were calculated on the basis of the Kaplan-Meier curves of cancer-specific survival. Thirty-day surgical mortality was estimated from the Steyerberg score, a validated risk score for mortality from esophagectomy by using 
SEER-Medicare data (Supplementary Methods
).
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Non-cancer-related death was predicted from the probability of death on the basis of age multiplied by the relative risk of death based on Charlson comorbidity index.
24,26
Costs and Utilities
Costs were based on published literature, converted to 2017 U.S. dollars by using the Consumer Price Index (U.S. Bureau of Labor Statistics). The cost estimate for ET of $1037.46 is the cost for one session. Quality-of-life measures were adjusted to utility scores for the specific health states: resectable cancer before therapy, 0.84; post-esophagectomy, 0.7 for the first postoperative month and 0.9 thereafter; and post-ET, 0.97. 23, 27, 28 These utilities were age-adjusted by multiplying by quality of life by age. 29 Costs and utilities were discounted at an annual rate of 3%. 30 
Outcomes
The primary outcomes of the analysis were unadjusted life years (life expectancy), QALYs, and incremental costeffectiveness ratio (ICER) between competing treatment strategies. The willingness-to-pay threshold was set at $100,000/QALY. 31 
Analyses Performed
A base case analysis using best estimates for all model parameters was performed separately for T1a and T1b EAC. One-way sensitivity analyses were performed to investigate the effects of each model parameter on estimated outcomes, including for age at diagnosis, Charlson comorbidity index, sex, health state utilities, and costs of procedure. To explore the interaction between age and comorbidity, two-way sensitivity analyses were performed for age at diagnosis and Charlson comorbidity index. Finally, because the relative utility estimates for post-esophagectomy and post-ET states were also key inputs for the model, two-way sensitivity analyses were also performed for these utilities.
Results
Base Case Results
The base case analyses of the T1a and T1b EAC cohorts are presented in Table 2 . For the T1a analysis, treatment with esophagectomy yielded 0.16 more unadjusted life years compared with ET but returned 0.27 fewer QALYs and cost $34,834 more. Therefore, the ET treatment strategy dominated esophagectomy for T1a EAC (resulted in more QALYs and cost less). For the T1b analysis, treatment with esophagectomy yielded 0.72 more unadjusted life years and 0.22 more QALYs, making it the more effective treatment strategy. However, esophagectomy was not cost-effective, with an ICER of $156,981/QALY.
Sensitivity Analysis
For the T1a EAC cohort, the results were only sensitive (preferred strategy changed) to relative utilities of post-esophagectomy and post-ET health states ( Figure 3A and B). Esophagectomy yielded the same or more QALYs if the ratio of post-esophagectomy utility to post-ET utility was 0.97 or greater. Esophagectomy was cost-effective if the ratio of post-esophagectomy utility to post-ET utility was 1.05 or greater. We also generated a model incorporating misdiagnosis, where a patient's T1a EAC was actually T1b. Sensitivity analysis was performed for probability of misdiagnosis between 0% and 100% because of the uncertainty in the true prevalence of this misclassification. At a probability of 55%, QALYs achieved with esophagectomy and ET become equal at 4.47; at a probability higher than 55%, esophagectomy provided more QALYs. There was no threshold at which esophagectomy was cost-effective compared with ET, even at a misdiagnosis probability of 100%. Other variables, including age and Charlson comorbidity index, did not change the optimal treatment strategy for the T1a cohort (Supplementary Table 2 ). Probabilistic sensitivity analysis did not find any willingness-to-pay threshold up to $300,000 for which esophagectomy was cost-effective compared to ET (Supplementary Figure 2 , Table 4 ).
For the T1b EAC cohort, results of key sensitivity analyses are summarized in Table 3 . The optimal treatment strategy was not affected by age at diagnosis alone, except with regard to cost-effectiveness. For age 70 at Table 3 ). Esophagectomy was cost-effective for age 60 with comorbidity index 0-1, but not at higher comorbidity indices. For ages 65 and 70, esophagectomy was cost-effective only for comorbidity index of 0.
As in the T1a analysis, the T1b model was also sensitive to relative utilities of the post-esophagectomy and post-ET health states ( Figure 3E and F) . ET became the optimal treatment strategy if the ratio of post-esophagectomy to post-ET utilities was 0.875 or less. Esophagectomy became cost-effective if the ratio of post-esophagectomy to post-ET utilities was 0.95 or greater. Probabilistic sensitivity analysis found esophagectomy cost-effective compared to ET in greater than 50% of iterations at a willingness-to-pay threshold of $220,000 (Supplementary Figure 3 , Table 4 ).
Discussion
Our modeling analysis confirmed that for T1a EAC, ET is the preferred treatment strategy across a range of ages and comorbidity indices, providing more QALYs and at a lower cost than esophagectomy. Although esophagectomy yielded slightly more unadjusted life years than ET for the T1a base case, we believe QALYs are a more important end point because of the significant morbidity associated with esophagectomy. With QALYs as the end point, the results were only sensitive to relative utilities of the post-esophagectomy and post-ET health states at a ratio of 0.97. Thus, if a patient considered his/her quality of life post-esophagectomy nearly equal to, or preferable to, his/her quality of life post-ET, esophagectomy would be the optimal treatment strategy. An example would be the patient who would rather have an esophagectomy than worry about recurrence with ET.
For T1b EAC, the optimal treatment strategy hinged on the combination of age at diagnosis and Charlson comorbidity index and again on relative utilities of posttreatment health states. For younger patients aged 60-70, esophagectomy was the preferred strategy at all comorbidity indices. However, for ages older than 70 with rising comorbidity index, the optimal strategy changed to ET. For the sickest patients, those aged 80 and older with comorbidity index of 2, ET not only provided more QALYs but more unadjusted life years as well. For the T1b cohort as well as the T1a cohort, relative utilities of post-esophagectomy and post-ET health states were a key driver of the optimal treatment strategy, reflecting the importance of the patient's perspective on quality of life after esophagectomy. With regard to cost-effectiveness, esophagectomy was only cost-effective for younger, healthier patients (ie, age 60-70 with comorbidity index of 0-1). In summary, for patients with local T1b cancers, the decision to treat with esophagectomy versus ET should be an individualized decision factoring in the patient's age, comorbidities, and quality of life preferences.
Our model has several limitations. For the T1a model, T1a tumors with more high-risk features, such as high-grade or lymphovascular invasion, may not be identified on endoscopic mucosal resection because of lack of standardization in pathology reporting of T1a cancers. Reporting these tumor features would allow for identification of higher-risk T1a patients, and a separate model should be performed to explore whether the preferred treatment strategy may differ for high-risk versus low-risk T1a tumors.
Our estimates of cancer-specific death were derived from the SEER-Medicare database. Because of limited numbers of T1b cancers treated with ET in the database, we chose to pool T1NOS cancers into our T1b cohort (Supplementary Methods). The T1NOS cohort performed the worst compared with T1a and T1b, likely representing tumors misclassified as T1b that may have been higher stage (Supplementary Figure 1) . This would have biased our analysis against ET because T1NOS patients made up 31% of the ET group compared with 11% of the esophagectomy group and overestimated the probability of cancer-related death for T1b patients treated with ET. Similarly, the staging of the SEER-Medicare database patients was heterogeneous because of practice variation in use of staging endoscopic mucosal resection, endoscopic ultrasound, and computed tomography or positron emission tomography imaging. This likely also biased the analysis against ET, because those patients were more likely to be under-staged because of lack of interrogation into regional lymph nodes that would be standard with esophagectomy. Also biasing against ET in our model was the inability to distinguish between "high risk" and "low risk" T1b tumors. 9, 13, 14 Because of successful outcomes of ET for low risk T1b cancers, generation of a separate model for low risk T1b adenocarcinomas might favor ET for a wider spectrum of patients. However, with its heterogeneous patient population, our analysis more closely reflects actual clinical practice.
Limitations of the model biasing against esophagectomy are largely related to cost. Our model did not incorporate costs of adjunctive therapies such as chemotherapy and radiation or palliative care, which are more likely in patients who do not undergo esophagectomy. 15, 16 In addition, we were unable to distinguish patients who failed serial ET and proceeded to esophagectomy from patients treated only with esophagectomy. In an intention-to-treat analysis, these patients would have been classified as ET (rather than as esophagectomy, as in our analysis), and the cost of esophagectomy would have been included in the total cost of their treatment. Lastly, our model did not capture more granular decrements in utilities such as stricture, metastatic disease, and complications of either treatment or progressive disease. These omissions likely overestimate the utility of the post-ET health state because stricture is a known risk of ET and progressive disease is more likely with ET.
Our model is overall biased against ET with regard to effectiveness, but despite this bias, it identifies a large cohort of patients for whom ET would provide more QALYs and even, for the oldest comorbid patients, more unadjusted life years. Our analysis supports the increasingly common practice of recommending ET for older comorbid patients, although it clarifies that age alone should not determine treatment, because noncomorbid older patients continue to have better outcomes with esophagectomy compared with ET. As improved estimates of survival for T1b EAC treated with ET emerge, an updated analysis would be warranted that might identify an even greater population of patients who would benefit from ET compared with esophagectomy.
In conclusion, our model analysis of T1a and T1b EAC supports the use of ET for T1a cancers and recognizes that optimal treatment for T1b cancer may be an individualized decision that should consider a patient's combination of age and comorbidity and his/her preferences regarding quality of life.
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Supplementary Methods
Model Transition Probabilities and Calibration
Probability of cancer-related death. Cancer-specific survival for T1b EAC treated with ET has only been reported in small studies with a wide range of estimates. Therefore, we calculated our own estimates of cancerspecific death for esophagectomy and ET on the basis of data from the November 2014 linkage of the SEER database by the National Cancer Institute. Patients were included if they had non-metastatic EAC diagnosed between January 1, 2000 and December 31, 2011 that could be classified as T1 cancer. A cancer was classified as EAC by using International Classification of Diseases for Oncology codes 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, and 8940-8941. Patients were classified into T subgroups by mapping the extension of disease variables to the appropriate stage by using the seventh edition of the American Joint Committee on Cancer Staging Manual, which is based on whether they only invaded the lamina propria or muscularis mucosa (T1a) or invaded the submucosa (T1b). Because of the small number of T1b tumors in the database, T1 tumors that were categorized as T1NOS were combined into the T1b group. Kaplan-Meier survival curves of T1a, T1b, and T1NOS tumors showed worst outcomes for T1NOS (treated with either ET or esophagectomy), suggesting that these tumors are likely T1b or higher stage rather than T1a (Supplementary Figure 1) . Exclusion criteria included cancers that were not the first primary cancer diagnosis, had evidence of lymph node involvement (N1), and lacked treatment information on receipt of surgery or local therapy. Patients were also excluded if they received radiotherapy treatment before surgery or local therapy or they were not continuously eligible for Medicare Part A and B for 13 months before diagnosis.
Patients who received esophagectomy or ET on the basis of Medicare claims were included (Supplementary Table 1 ). Because use of both SEER and Medicare claims may enhance identification of cancer surgery, patients receiving ET according to SEER with no Medicare claims for esophagectomy were classified in the ET group, and those receiving esophagectomy according to SEER were classified in the surgery group.
The comorbidity score was estimated by applying the adaptation by Deyo et al of the Charlson comorbidity index to Medicare inpatient, outpatient, and physician claims during the 13-month period before cancer diagnosis and classified into the groups 0, 1, and 2þ. 26 Survival was measured from cancer diagnosis to death or December 31, 2013, whichever came first. Patients were identified as having died of their cancer on the basis of the cause of death variable in SEER. Cancer-specific survival curves were generated by using Kaplan-Meier. All statistical analyses were performed by using SAS software, version 9.4 (SAS Institute, Inc, Cary, NC).
Kaplan-Meier curves were generated to compare overall survival between treatment groups, with those alive on December 31, 2013 censored (Figure 2) . Hazard rates were calculated on the basis of the Kaplan-Meier curves of cancer-specific survival. Procedural mortality was excluded from these rates and accounted for as a separate input in the model. Thirty-day surgical mortality was estimated from the Steyerberg score, a validated risk score for mortality from esophagectomy derived from data from the SEER-Medicare database (Supplementary Methods). 18 Kaplan-Meier curves were generated to compare overall survival between treatment groups (Figure 2) . Hazard rates were calculated on the basis of the Kaplan-Meier curves of cancer-specific survival. Procedural mortality was excluded from these rates and accounted for as a separate input in the model. Non-cancer-related death was predicted from the probability of death on the basis of age multiplied by the relative risk of death based on Charlson comorbidity index. 24, 26 Surgical mortality. This score incorporates the major risk-conferring and protective factors that predict the surgical mortality for a patient: age, number of comorbidities, whether patients had received neoadjuvant therapy with radiation or chemotherapy, and hospital volume of esophagectomies per year (with higher volume conferring protection against surgical mortality). For our model, the input for number of comorbidities was the Charlson comorbidity index. All patients were assumed to have not received neoadjuvant therapy. Hospital volume was set at "very high." 
